282 related articles for article (PubMed ID: 29847570)
1. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
Drent E; Poels R; Mulders MJ; van de Donk NWCJ; Themeli M; Lokhorst HM; Mutis T
PLoS One; 2018; 13(5):e0197349. PubMed ID: 29847570
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
3. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
[TBL] [Abstract][Full Text] [Related]
5. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Drent E; Themeli M; Poels R; de Jong-Korlaar R; Yuan H; de Bruijn J; Martens ACM; Zweegman S; van de Donk NWCJ; Groen RWJ; Lokhorst HM; Mutis T
Mol Ther; 2017 Aug; 25(8):1946-1958. PubMed ID: 28506593
[TBL] [Abstract][Full Text] [Related]
6. Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety.
Gu X; He D; Li C; Wang H; Yang G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400287
[TBL] [Abstract][Full Text] [Related]
7. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
[TBL] [Abstract][Full Text] [Related]
8. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
9. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
Hambach J; Riecken K; Cichutek S; Schütze K; Albrecht B; Petry K; Röckendorf JL; Baum N; Kröger N; Hansen T; Schuch G; Haag F; Adam G; Fehse B; Bannas P; Koch-Nolte F
Cells; 2020 Jan; 9(2):. PubMed ID: 32013131
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors.
Mihara K; Yoshida T; Ishida S; Takei Y; Kitanaka A; Shimoda K; Morishita K; Takihara Y; Ichinohe T
Blood Cancer J; 2016 May; 6(5):e421. PubMed ID: 27176797
[No Abstract] [Full Text] [Related]
12. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
Cohen AD
Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
[TBL] [Abstract][Full Text] [Related]
14. CARs in the Lead Against Multiple Myeloma.
Ormhøj M; Bedoya F; Frigault MJ; Maus MV
Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
[TBL] [Abstract][Full Text] [Related]
15. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
Ebert LM; Yu W; Gargett T; Brown MP
Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy.
Zhang RY; Wei D; Liu ZK; Yong YL; Wei W; Zhang ZY; Lv JJ; Zhang Z; Chen ZN; Bian H
Front Cell Dev Biol; 2019; 7():233. PubMed ID: 31681766
[TBL] [Abstract][Full Text] [Related]
17. Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation.
An N; Pan Y; Yang L; Zhang Q; Deng S; Zhang Q; Du X
Mol Pharm; 2023 May; 20(5):2426-2435. PubMed ID: 37021820
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
[TBL] [Abstract][Full Text] [Related]
19. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
20. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
